UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Nature reviews. Drug discovery, 2002-07, Vol.1 (7), p.493-502

2002

Volltextzugriff (PDF)

Imatinib: a selective tyrosine kinase inhibitor

European journal of cancer (1990), 2002-09, Vol.38, p.S19-S27

2002

Volltextzugriff (PDF)

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class

Cancer research (Chicago, Ill.), 2000-09, Vol.60 (18), p.5143-5150

2000

Volltextzugriff (PDF)

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Blood, 2005-04, Vol.105 (7), p.2640-2653

2005

Volltextzugriff (PDF)

Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2- Phenylaminopyrimidine Class

Proceedings of the National Academy of Sciences - PNAS, 1995-03, Vol.92 (7), p.2558-2562

1995

Volltextzugriff (PDF)

Pharmacology of imatinib (STI571)

European journal of cancer (1990), 2002-09, Vol.38, p.S28-S36

2002

Volltextzugriff (PDF)

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

The Journal of pharmacology and experimental therapeutics, 2000-10, Vol.295 (1), p.139

2000

Volltextzugriff (PDF)

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

The New England journal of medicine, 2001-04, Vol.344 (14), p.1031-1037

2001

Volltextzugriff (PDF)

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

Cancer research (Chicago, Ill.), 2004-04, Vol.64 (7), p.2333-2337

2004

Volltextzugriff (PDF)

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia

Nature genetics, 2004-05, Vol.36 (5), p.453-461

2004

Volltextzugriff (PDF)

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

Cancer research (Chicago, Ill.), 2002-10, Vol.62 (19), p.5476-5484

2002

Volltextzugriff (PDF)

The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

Clinical cancer research, 2005-02, Vol.11 (4), p.1563-1571

2005

Volltextzugriff (PDF)

The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth

Clinical cancer research, 2000-08, Vol.6 (8), p.3319-3326

2000

Volltextzugriff (PDF)

Tyrosine kinase inhibitors: From rational design to clinical trials

Medicinal research reviews, 2001-11, Vol.21 (6), p.499-512

2001

Volltextzugriff (PDF)

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

Cancer research (Chicago, Ill.), 2001-04, Vol.61 (7), p.2929-2934

2001

Volltextzugriff (PDF)

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Nature medicine, 1996-05, Vol.2 (5), p.561-566

1996

Volltextzugriff (PDF)

Patupilone (epothilone B, ep0906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

Cancer chemotherapy and pharmacology, 2005-04, Vol.55 (4), p.307-317

2005

Volltextzugriff (PDF)

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Cancer research (Chicago, Ill.), 2000-04, Vol.60 (8), p.2178-2189

2000

Volltextzugriff (PDF)

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

The Journal of biological chemistry, 2002-08, Vol.277 (35), p.32214-32219

2002

Volltextzugriff (PDF)

STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake

Clinical cancer research, 2003-09, Vol.9 (10), p.3779-3787

2003

Volltextzugriff (PDF)

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

Cancer research (Chicago, Ill.), 2000-06, Vol.60 (11), p.2926-2935

2000

Volltextzugriff (PDF)

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Pharmacology & therapeutics (Oxford), 2002-02, Vol.93 (2), p.79-98

2002

Volltextzugriff (PDF)

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

JNCI : Journal of the National Cancer Institute, 1999-01, Vol.91 (2), p.163-168

1999

Volltextzugriff (PDF)

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis

Cancer research (Chicago, Ill.), 2001-08, Vol.61 (15), p.5778-5783

2001

Volltextzugriff (PDF)

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Blood, 1997-12, Vol.90 (12), p.4947-4952

1997

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(74)
Tagungsberichte
(2)

Sprache

Englisch
(76)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(53)
Animals
(44)
Biological And Medical Sciences
(44)
Medical Sciences
(43)
Humans
(35)
Pharmacology. Drug Treatments
(34)
Pyrimidines - Pharmacology
(34)
Benzamides
(33)
Imatinib Mesylate
(33)
Mice
(30)
Antineoplastic Agents
(29)
Enzyme Inhibitors - Pharmacology
(26)
Antineoplastic Agents - Pharmacology
(25)
Oncology
(22)
Protein-Tyrosine Kinases - Antagonists & Inhibitors
(21)
Cell Division - Drug Effects
(20)
Piperazines - Pharmacology
(19)
Pharmacology & Pharmacy
(17)
Mice, Inbred Balb C
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Imatinib: a selective tyrosine kinase inhibitor

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2- Phenylaminopyrimidine Class

Pharmacology of imatinib (STI571)

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1 -induced B-lymphoblastic leukemia but not chronic myeloid leukemia

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth

Tyrosine kinase inhibitors: From rational design to clinical trials

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Patupilone (epothilone B, ep0906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Suchergebnisse filtern